Jnpmedi lands 5B won government grant to build AI 'Clinical OS

What's the deal? Jnpmedi, an AI-based life science R&D platform company, has secured a 5 billion won (about $3.6 million) grant from South Korea's Ministry of SMEs and StartupsDealroom has a profile for this one. Try Dealroom →. The award came through the ministry's 2026 Global TIPS General Type program, which backs the technology development and overseas expansion of small and medium venture companies.

What's the money for? Jnpmedi will use it to build an AI-based "Clinical OS," an operating system that connects clinical trial data, documents, global regulatory information, and operational tasks in a single environment. Core features include AI document generation, anomaly and pattern detection in trial data, regulatory compliance checks, and automation of clinical operations.

Why now? Drug development scatters trial data, documents, and regulatory work across separate systems and teams. As studies span more countries, reviewing data and verifying compliance grows more complex; adding AI to individual tasks doesn't stitch those steps into one flow, the company argues.

What's the endgame? Including the grant, Jnpmedi has secured a total of 6.2 billion won in project funding through June 2030. It plans to build a minimum viable product, validate core technology, then expand testing with overseas pharma and biotech firms and contract research organisations (CROs).

Chief executive officer Jung Kwon-ho said the selection would combine the company's "clinical trial operation expertise and data and platform technology with AI to raise global competitiveness."

The signal: The award ranks among the larger South Korean grant rounds, sitting in roughly the 90th percentile of 155 comparable deals. It reflects government appetite to back domestic AI startups aiming squarely at global pharma and CRO markets.

Read more: venturesquare.net

Image credit: Generated with Gemini